Speaking at The New York Times’s DealBook Summit, Eli Lilly’s chief executive and an obesity medicine specialist discussed ...

The push to develop the first oral GLP-1 receptor drug for obesity is heating up, as four phase 3 drugs race to become the first approved oral treatment for obesity, Global Data reported Dec. 2. Here ...

Ozempic maker Novo Nordisk says it has developed a compound that’s shown to be a one-two punch for appetite suppression and ...

Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...

More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

Participants in Wegovy clinical trials were more likely to report “severe gastrointestinal adverse reactions,” the FDA's ...

Brand companies who own GLP-1 products have been pushing the Food and Drug Administration (FDA) to limit their compounding. On August 28, 2024, ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...

Research has found that while treatments such as liraglutide (Victoza) and tirzepatide may result in expected muscle loss in line with weight reduction, they can also improve muscle quality. However, ...

For employers wanting to dip a toe into the GLP-1 medications pool, utilization management is recommended to control costs.

New research reveals that popular diabetes and weight-loss drugs may also protect the kidneys. This groundbreaking study, ...